The Hedge Book logo The Hedge Book Read smarter. Invest better.

AI Stock Monitor

JNJ - Johnson & Johnson

Johnson & Johnson is a North America covered company in The Hedge Book research universe.

Public company · North America · Healthcare · Pharmaceuticals · Medical Devices · Dow constituent

NYSE · Healthcare · Research updated · Market data updated Research and source refreshes run four times daily. The timestamps above identify the latest successful research and market-data updates.
Hedge Score 65 /100
BullishBullish
Confidence85%
Community Bullish0%
Followers0
Current Price$270.471D +1.2%

Price History

JNJ chart

285.75249.83213.90177.98142.06 Nov 2023May 2024Nov 2024May 2025Nov 2025May 2026Nov 2026 2023-11-20 152.502025-05-26 155.212026-11-20 270.47

AI-Assisted Chart Analysis

Johnson & Johnson technical analysis

Calculated from verified chart history for the selected tenor; no news or fundamental assumptions are used.

Technical only
Trend

Mixed trend: the latest level is above its 20-period average, without full long-term confirmation.

Momentum

RSI is 50, a neutral reading. Above 70 can signal extension; below 30 can signal exhaustion.

Support scenario

The first technical watch zone is 253.04. A break below 186.57 invalidates the near-term support setup.

Resistance scenario

The first resistance/watch zone is 285.75. A confirmed break above 285.75 supports continuation.

Risk

Annualized realized volatility is +41.6%. Maximum lookback drawdown is -14.3%, from a high-water mark of 165.86 to 142.06.

Potential levels are conditional chart scenarios, not personalized advice or instructions to buy or sell.

How To Read This Stock Brief
Hedge Score

Higher means the current research setup is stronger across signal, confidence, catalysts, risk balance, and market context. Lower means the setup is weaker or less supported.

Confidence

Higher confidence means the evidence is more consistent and relevant. It does not mean the stock has that percentage chance of going up.

Signal

Bullish, Bearish, or Neutral is the current AI research stance. It is designed to help you ask better questions, not to replace your decision process.

Community Bullish

This shows how signed-in users are voting. It is useful sentiment context, not proof that the crowd is right.

Read the full Hedge Score and confidence methodology

What Changed Today

  • Yahoo Finance delayed market data reported JNJ at 270.47 USD; the latest daily move rose +1.25%. This is a verified market-price signal only and does not by itself confirm a change in company fundamentals.

Why It Matters

  • The verified +1.25% daily move is current market context for Johnson & Johnson.
  • It can affect near-term sentiment, but price action alone does not establish a change in earnings, asset quality, competitive position, valuation, catalysts, or risks.
  • Those require a separately sourced filing or company update.

AI Opinion

  • Read: The signal is Bullish, supported by a flurry of positive clinical and operational developments over the past week.
  • Evidence: The successful initiation of the Ottava commercial rollout and the acquisition of Ollin Biosciences demonstrate active portfolio management and growth-oriented capital allocation.
  • Uncertainty: Clinical data for TREMFYA and prostate cancer treatments provide tangible evidence of a robust pipeline that can drive future earnings.
  • Watch: However, the legal loss in Louisiana underscores that litigation remains a significant, unresolved risk factor that could periodically dampen investor sentiment.

Key Risks

  • Ongoing talc litigation remains a material risk, as evidenced by the recent Louisiana appellate court loss, which could lead to further financial settlements or judgments.
  • The surgical robotics market is highly competitive, and J&J faces significant hurdles in gaining market share from established players like Intuitive Surgical and Medtronic.
  • Integration of the newly acquired Ollin Biosciences carries execution risk, and the long-term commercial success of the acquired pipeline assets is not guaranteed.

Upcoming Catalysts

  • Successful expansion of the Ottava robotic system into additional hospitals will be a key indicator of commercial traction and potential revenue contribution.
  • Regulatory updates regarding the sNDA submission for CAPLYTA in bipolar mania would serve as a near-term catalyst for the pharma segment.
  • Continued positive clinical data readouts from the oncology and immunology pipelines will be critical to sustaining investor confidence in long-term growth.

Upcoming Events

No verified update available

Last Updated

Sources and verification

Each generated research claim remains linked to its supporting update. Primary evidence comes from filings, company materials, or regulators; secondary evidence provides additional context.

  • Published stock briefSecondary sourceReportedSector Update: Healthcare Stocks Rise Late Afternoon · Published 2026-11-21 01:06:13Open verification sourceSupports: Published stock brief
  • Published stock briefSecondary sourceReportedThese 4 Conservative Dow Jones Industrials Dividend Stocks Are Built for Sell-Offs · Published 2026-11-21 01:06:13Open verification sourceSupports: Published stock brief
  • Published stock briefSecondary sourceReportedHow Retirees Can Turn $750,000 Into Passive Income With These 5 Dividend Stocks · Published 2026-11-21 01:06:13Open verification sourceSupports: Published stock brief
  • Published stock briefSecondary sourceReportedJ&J to install first Ottava robot in US hospital · Published 2026-11-21 01:06:13Open verification sourceSupports: Published stock brief
  • Published stock briefSecondary sourceReportedMoney Market Funds vs. Dividend Stocks: Where Retirees Should Keep Their Cash · Published 2026-11-21 01:06:13Open verification sourceSupports: Published stock brief
Market-data attributionYahoo Finance delayed market data · provider detailsMarket prices are supporting signals only and do not establish the research conclusion.

Community View

Sign in with Google to vote once per stock.

Bullish
Bearish
Neutral

Total votes: 0

Disclaimer

The Hedge Book provides AI-assisted educational market research. It is not a registered investment adviser, broker, dealer, or financial planner. Content may contain errors and should be independently verified. Do not treat this page as personalized advice to buy, sell, or hold any security.